- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Company Partners with BARDA to Advance SCY-247 Development
What happened
The company announced a partnership with BARDA to accelerate the development of SCY-247. This collaboration provides non-dilutive funding and allows the company to advance two programs into Phase 2. The company stated it does not anticipate any changes to its guidance regarding its lead product candidate, SCY-770, or its cash runway into 2029.
From manilatimes.net
Why it matters
The partnership focuses on developing a novel therapy for serious invasive fungal infections, addressing a critical public health need. The funding strengthens the company's pipeline and its long-term value proposition by leveraging existing infrastructure.
The company is currently conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
From manilatimes.net
Who's involved
- CompanyThe company entered into a partnership with BARDA to advance SCY-247.
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
- BioPorto is seeking regulatory pathways and activating its first clinical site in collaboration with Massachusetts General Hospital.
- Veradermics, Incorporated is seeking federal regulatory approval from the FDA for its drug candidates.